Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

Item
http://www.wikidata.org/entity/Q37809277
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome studyBiospecimens and biorepositories for the community pathologist.Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia.Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.The Effect of Structured Education to Patients Receiving Oral Agents for Cancer Treatment on Medication Adherence and Self-efficacy.Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
P2860

Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

Item
http://www.wikidata.org/entity/Q37809277
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
@en
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
@nl
type
label
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
@en
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
@nl
prefLabel
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
@en
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
@nl
P1433
P1476
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
@en
P304
P31
P356
10.1016/J.CANLET.2010.10.018
P407
P433
P478
P50
P577
P698
P921